Lv11
50 积分 2023-04-10 加入
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023
1个月前
已完结
Balancing weight and muscle loss in GLP1 receptor agonist therapy
1个月前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1个月前
已完结
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults
1个月前
已完结
Beyond weight loss: multisystem benefits of obesity medications
1个月前
已完结
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions
1个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
1个月前
已完结
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions
1个月前
已完结
皖公网安备34019202002308
